Because of the findings of these large studies, the de novo subtypes of CEBPA-mutated AML in the new classification systems have been updated to “AML with in-frame bZIP CEBPA mutations” in ICC and “AML with CEBPA mutation” in WHO5, with the caveat that in WHO5, the acceptable mutations are either biallelic (biCEBPA) or single mutations in the bZIP domain (smbZIP-CEBPA). The gene discussed is CEBPA; the disease is intrahepatic cholangiocarcinoma.